Research information only, not medical advice. In clinical trials, retatrutide was given as a once-weekly subcutaneous injection at 4 mg, 9 mg, or 12 mg. These are the doses studied in supervised research; retatrutide is investigational and not approved, and this is not a dosing recommendation.
The doses evaluated for retatrutide come from its randomized controlled trials, not from an approved label — retatrutide has none. In a 40-week phase 3 trial in adults with type 2 diabetes, participants received once-weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg (Bajaj et al.). Phase 2 obesity trials evaluated a range of once-weekly doses up to 12 mg. Because retatrutide is investigational, no dose is established as safe or effective outside a clinical trial: this page reports the doses studied, not a protocol to follow.
For the full evidence base, clinical trials, and regulatory status, see the Retatrutide research overview . Related: retatrutide side effects , retatrutide benefits .
Sources
Frequently asked questions
- What doses of retatrutide were used in trials?
- A phase 3 type 2 diabetes trial used once-weekly subcutaneous retatrutide at 4 mg, 9 mg, and 12 mg; phase 2 obesity trials evaluated doses up to 12 mg once weekly.
- Is there an approved retatrutide dose?
- No. Retatrutide is investigational and has no FDA-approved label or established dose; the figures above describe doses studied in trials, not a recommendation.
Updated · sourced to primary documents